PD-1 antibody added to the DEP regimen （with or without asparaginases） in EBV-HLH,
This study aimed to investigate the efficacy and safety of DEP (liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for EBV associated hemophagocytic lymphohistiocytosis.